Drugs / MTx-COVAB36
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05351437 Comparator | Apr → Sep 2022 | COVID-19 | Memo Therapeutics AG | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MTx-COVAB36 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05351437 ↗ |
| Modality | Monoclonal antibody | “fully human monoclonal IgG1 antibody” NCT05351437 ↗ |
| Route | Intravenous | “MTx-COVAB36 will be administered as a single dose intravenously.” NCT05351437 ↗ |